Gilead claims to have received positive data on ridxivir: clinical results vary by region

Gilead claims to have received positive data on ridxivir: clinical results vary by region
Sauna Night News (Reporter Li Yunqi) On the evening of April 29th, Beijing time, U.S.-listed company Gilead Sciences issued a statement saying that the company has been informed that the National Institute of Allergy and Infectious Diseases (NIAID) is aimed at researching the antiviral drug Redox(Remdesivir) The treatment of new coronavirus pneumonia has produced positive data.  In the early hours of April 30th, Gilead announced the top-line results of the open-label SIMPLE phase III clinical trial, which evaluated severely hospitalized patients with new coronavirus pneumonia and received 5 days of study antiretroviral drug RidesivirAnd the expected therapeutic effect for 10 days.Studies have shown that the clinical improvement similarity between patients receiving 5-day course of reduxil and patients receiving 10-day course of reduxil (OR value: 0.75 [95% CI 0.51-1.12], on the 14th day).  Gilead claims that in this study, 50% of patients had clinical improvement time of 10 days in the 5-day treatment group and 11 days in the 10-day treatment group.More than half of the patients in both treatment groups were discharged from 14 adolescents.On day 14, the treatment group was 64 on 5 days.5% of patients and the 10-day treatment group 53.8% of patients achieved clinical recovery.  In addition, clinical results also vary by region.Except for Italy, the overall mortality rate on day 14 in both treatment groups was 7%, of which 64% of patients had clinical improvement on day 14 and 61% of patients were discharged.  In the Air Force ‘s April 23, foreign media cited the World Health Organization ‘s accidental document index report that Gilead ‘s potential anti-new coronavirus drug Ridexivir failed in the first randomized clinical trial. On the same day, Gilead Sciences issued a public statement saying that the World Health Organization released information about China ‘s first clinical study prematurely. The article contains an inappropriate description of the study. “The study was terminated early due to the low enrollment rate.Therefore, its data is insufficient to support statistically significant copies.”Reporter Li Yunqi edited Sun Yong proofreading Wei Zhuo